预约演示

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

2023-08-14

交易

临床3期并购临床1期临床2期

Phalguni Deswal

@Phalguni_GD

The shareholders would also be eligible to receive an additional $4 per share contingent (totalling $300m) on regulatory milestones. Image Credit: JHVEPhoto / Shutterstock.

Novartis has acquired Chinook Therapeutics for more than $3.2bn in a move to bolster its portfolio of drugs targeting kidney disease.

With reported sales of $13.62bn in Q2 2023, Novartis is looking to expand its drug portfolio. Just last month, the company acquired DTx Pharma for $1bn for its small interfering RNA (siRNA) treatment portfolio for rare diseases.

Novartisded ReportsChinook Therapeutics kidney disease

ReportsChronic Myeloid Leukemia (CML): GlobaNovartisorecast and Market Analysis to 2030 GlobalDataDTx Pharma

ReportsHER2+ Breast Cancer - Global Drug Forecast and Market Analysis to 2030 GlobalData

View allCompanies IntelligenceNovartis AGChinook Therapeutics IncEra SpaDTx Pharma IncKidney Research UKView all

As partChronic Myeloid Leukemia (CML) shareholders would receive $40 per share, totalling $3.2bn. The shareholders would also be eligible to receive an additional $4 per share contingent (totalling $300m) on regulatory milestones.

The acquisition comes at a significant inflection point with two high-profile drugs, atrasentan and zigakibart, in Phase III development for the treatment of IgA nephropathy (IgAN). A pivotal data readout for the Phase III atrasentan trial is planned for Q4 2023.

IgAN is a chrBreast Cancerisease, in which immunoglobulin A (IgA) is trapped in the glomeruli of the kidney, thereby causing kidney scarring and damage. As per the charity Kidney Research UK, the current treatment for the disease includes symptomatic control, blood pressure medications that can also reduce proteinuria (a common symptom of IgAN), and immunosuppressants.

Zigakibart is a subcutaneous monoclonal antibody that targets a proliferation-inducing ligand (APRIL). The Phase III trial began in July 2023, with the goal of enrolling 272 participants. The primary endpoint for the study is the change in proteinuria from baseline in the treatment group, compared to a placebo.

Atrasentan Chinookral endothelin A receptor antagonist (ERA), which is currently in a placebo-controlled Phase III trial (NCT04573478) for IgAN. Based on available data, Chinook says atrasentan causes a significant reduction in proteinuria compared to placebo.

Chinook’s portfolio also consists of drugs in early phases of development including Catrasentanr trezigakibartary hyperoxaluria (PH) and other kidney stone diIgA nephropathy (IgAN)nt is on pause due to a serious adverse eveatrasentand in its Phase I study.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构